WP
AVTX icon

Woodline Partners’s Avalo Therapeutics AVTX Stock Holding History

Woodline Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Buy
+12,544
New +$198K ﹤0.01% 1004
2026
Q1 		– Sell
-52,041
Closed -$945K – 1036
2025
Q4 		$945K Buy
+52,041
New +$878K ﹤0.01% 844

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Woodline Partners's AVTX Position: Q2 2026 in Review

Woodline Partners opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 12,544 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #1004 among its holdings. This is a return to the name: Woodline Partners previously reported a position in AVTX as recently as Q4 2025.

Woodline Partners first reported a position in AVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $945K in Q4 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Woodline Partners held 12,544 shares of Avalo Therapeutics worth $232K as of Q2 2026.
  • Avalo Therapeutics was a new Woodline Partners position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #1004 holding.
  • Woodline Partners first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Woodline Partners's Avalo Therapeutics position peaked at $945K in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.